Activation of Hippo/YAP signaling pathway exacerbates vascular remodeling and aggravates hypertension by upregulating Foxm1
- PMID: 40388085
- DOI: 10.1007/s10735-025-10443-1
Activation of Hippo/YAP signaling pathway exacerbates vascular remodeling and aggravates hypertension by upregulating Foxm1
Abstract
The Hippo/YAP signaling pathway is closely related to the occurrence and development of cardiovascular diseases. However, it's still unclear whether this pathway plays a certain role in hypertension. In this study, aortic morphology and function in spontaneously hypertensive rats (SHR) were comprehensively evaluated using Wistar-Kyoto rats (WKY) as controls. Results indicated that the aorta of SHRs have distinct changes in pathological structure. Furthermore, the proliferative activity of vascular smooth muscle cells (VSMCs) was enhanced, with vascular fibrosis being aggravated. Immunohistochemical analysis revealed that SHRs exhibited high expression of Yes-Associated Protein (YAP). Western Blot analysis showed that cytoplasmic YAP and TAZ expression decreased in hypertensive rats, indicating that YAP/TAZ nuclear transfer increased and Hippo/YAP signaling pathway had been activated. The cell function experiments of VSMCs extracted from rat aorta showed that the cell viability and proliferation ability of VSMCs in SHRs were enhanced, the expression of Fibronectin and collagen I was increased, and vascular fibrosis was aggravated. siRNA-YAP (si-YAP) can reverse the above phenomenon in VSMCs. Knockdown of YAP can inhibit Foxm1 expression. As an inhibitor of large tumor suppressor kinases LAST1/2, GA-107 can inhibit the phosphorylation level of YAP, increase blood pressure, aggravate aortic pathomorphological changes, promote VSMCs proliferation and vascular fibrosis, and thus aggravate hypertension symptoms in SHRs. However, these effects of GA-107 can be antagonized by inhibiting Foxm1 with thiosulfathiazole (Thio). Conclusively, Hippo/YAP signaling pathway promotes vascular remodeling through the regulation of Foxm1 and causes hypertension.
Keywords: Foxm1; Hippo/YAP signaling pathway; Hypertension; VSMCs; Vascular remodeling.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Ethics approval and consent to participat: All the animal experimental procedure were conducted in accordance with the international standards stated in Guidelines for the Care and Use of Laboratory Animals. And all the animal protocols were approved by the Committee on the Ethics of Animal Experiments of Shaanxi Provincial People’s Hospital.
Similar articles
-
Exomeres From Adventitial Fibroblasts of Spontaneously Hypertensive Rats Promote Vascular Remodelling via Transferring Osteopontin.J Extracell Vesicles. 2025 Aug;14(8):e70146. doi: 10.1002/jev2.70146. J Extracell Vesicles. 2025. PMID: 40767027 Free PMC article.
-
Exploring Hippo YAP/TAZ Signaling: A Novel Avenue for Cardiovascular Disorders.Cell Biol Int. 2025 Sep;49(9):1079-1101. doi: 10.1002/cbin.70052. Epub 2025 Jul 14. Cell Biol Int. 2025. PMID: 40654305 Review.
-
The role of LNK in mitigating hypertension: inhibition of vascular smooth muscle proliferation and JAK-STAT pathway.Mol Cell Biochem. 2025 Jul;480(7):4107-4118. doi: 10.1007/s11010-025-05237-8. Epub 2025 Feb 27. Mol Cell Biochem. 2025. PMID: 40014199
-
Vascular smooth muscle-specific LRRC8A knockout ameliorates angiotensin II-induced cerebrovascular remodeling by inhibiting the WNK1/FOXO3a/MMP signaling pathway.Acta Pharmacol Sin. 2024 Sep;45(9):1848-1860. doi: 10.1038/s41401-024-01280-1. Epub 2024 May 8. Acta Pharmacol Sin. 2024. PMID: 38719954
-
Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2023 Nov;149(16):15311-15322. doi: 10.1007/s00432-023-05272-2. Epub 2023 Aug 22. J Cancer Res Clin Oncol. 2023. PMID: 37608027 Free PMC article. Review.
References
-
- Cunningham R, Hansen CG (2022) The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci 136(3):197–222
-
- de Oliveira MG, Nadruz W Jr., Mónica FZ (2022) Endothelial and vascular smooth muscle dysfunction in hypertension. Biochem Pharmacol 205:115263 - PubMed
-
- Dong ZC, Wu MM, Zhang YL, Wang QS, Liang C, Yan X et al (2021) The vascular endothelial growth factor trap Aflibercept induces vascular dysfunction and hypertension via Attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin 42(9):1437–1448 - PubMed
MeSH terms
Substances
Grants and funding
- 021JY-28/Science and Technology Talent Support Program of Shaanxi Provincial People's Hospital
- KLMC-2018-04/Open Project of Shaanxi Provincial Key Laboratory of Molecular Cardiology
- 2022YJY-51/Science and Technology Development Incubation Fund of Shaanxi Provincial People's Hospital
- 2024JC-YBMS-754/Natural Science Foundation of Shaanxi Province
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous